Similar effects on HbA1c were observed in both treatment groups (Table 4)
The emergence of a metabolic drug that incidentally reduces addictive behavior underscores something many clinicians have long suspected: addiction is deeply intertwined with the bodys fundamental regulatory systems appetite, satiety, stress, reward, inflammation including behaviors like binge eating that share overlapping neural pathways
This is especially important in the GLP-1 era because demand has outstripped access, many people struggle with tolerability or long-term adherence, and the market is rapidly expanding beyond drugs into foods, supplements, and functional ingredients that can help more people participate in the benefits of GLP-1aligned metabolic support
Third-party testing also checks for harmful substances such as heavy metals, pesticides, and more for safety
Young: Yeah, tirzepatide got lifted off of the shortage list in, I think, late 2024, and then semaglutide followed in 2025